Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials.
Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience P, Nilsson M, Klevebro F, Tan L, Zhang S, Aparicio T, Piessen G, van der Zijden C, Mostert B, Wijnhoven BPL, Tsushima T, Takeuchi H, Kato K, Kitagawa Y.
Okui J, et al. Among authors: tan l.
Br J Surg. 2025 May 31;112(6):znaf131. doi: 10.1093/bjs/znaf131.
Br J Surg. 2025.
PMID: 40568913
Free PMC article.